Shows promising non-invasive molecular phenotyping of breast cancer via ultrasound, indicating its potential utility for therapy guidance.
Molecular subtyping is essential for guiding systemic therapy in breast cancer but currently requires invasive biopsy. Conventional B-mode ultrasound offers rich anatomical information, yet lacks the functional dynamics needed to capture the comprehensive biology of tumors. Here, we present the first multimodal ultrasound spatiotemporal transformer, MUST-Sub, which integrates paired B-mode morphological features with contrast-enhanced ultrasound (CEUS) hemodynamic patterns to classify Luminal, HER2-enriched, and triple-negative subtypes. Training on a retrospective development cohort, and validated on internal, prospective, and multicenter external cohorts, MUST-Sub achieved macro-average areas under the receiver operating characteristic curve (AUCs) of 0.94, 0.90, and 0.92, respectively, and Luminal versus non-Luminal AUCs of 0.92, 0.88, and 0.91, outperforming B-mode-only deep learning baselines. MUST-Sub also produced interpretable quantitative biomarkers derived from spatiotemporal attention: the morphology-associated biomarker showed inverse correlations with tumor size (Spearman ρ = [- 0.34, - 0.23]; all p < . 05), while the hemodynamics-associated biomarker correlated positively with tumor size (ρ = [0.24, 0.32]; all p < . 05) and Ki-67 proliferation index (ρ = [0.21, 0.24]; all p < . 05). These results suggest that multimodal ultrasound with spatiotemporal modeling can serve as a promising adjunctive approach for non-invasive pre-biopsy molecular phenotyping of breast cancer.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: